A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Quest launches residual disease blood test for multiple myeloma
Quest launches residual disease blood test for multiple myeloma
How Mirum is Advancing Rare Disease Care Through Strategic M&A
How Mirum is Advancing Rare Disease Care Through Strategic M&A
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
Novo’s CagriSema tops semaglutide in ph. 3 diabetes study
GSK gives back rights to Wave's genetic disease RNA editor
GSK gives back rights to Wave's genetic disease RNA editor
Thermo Fisher trims Massachusetts headcount with Franklin site closure
Thermo Fisher trims Massachusetts headcount with Franklin site closure
GSK plans to lay off up to 350 R&D workers across US, UK
GSK plans to lay off up to 350 R&D workers across US, UK
Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
Roche's return to RNA continues with $1.7B deal for Sanegene program
Roche's return to RNA continues with $1.7B deal for Sanegene program
Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative
Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative
China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug
China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug
Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again
Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection
AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection
CRO Sygnature Discovery plans to send 60 UK staffers packing
CRO Sygnature Discovery plans to send 60 UK staffers packing
Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate
Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page